Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AMD stock jumps as chip rally builds ahead of summit
Amarin Corp. (AMRN) Misses Q3 EPS by 2c, Revenues Beat
February 27, 2019 5:59 AM ESTAmarin Corp. (NASDAQ: AMRN) reported Q3 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $77.33 million versus the consensus estimate of $73.87 million.
Net product revenue for the years ended December 31, 2018 and 2017 was $228.4 million and $179.8 million, respectively. Net product revenue for the three months ended December 31, 2018 and 2017 was $77.1 million and $53.5 million, respectively. Increased revenue is mainly attributed to increased Vascepa prescriptions in the U.S.In addition, Amarin recognized licensing revenue of $0.8 million and $1.3 million for the years ended December 31, 2018 and 2017, respectively, under... More